Skip to content

SUPERSTRING CAPITAL MANAGEMENT LP

Follow

13F filer, CIK 1931118, NEW YORK, NY

SUPERSTRING CAPITAL MANAGEMENT LP reported $199,517,915 across 35 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 59.45% of the portfolio.

Accepted , ingested 13F-HR 0001931118-26-000011

Period
2026-09-30
Reported value
$200M
Holdings
35
Top 10 weight
59.45%
New
12
Sold out
9

Largest buys vs the previous quarter

SecurityShares changeApprox. value
AXSMadded+48,569$8.96M
COGTadded+254,124$8.14M
LEGNnew+357,359$7.11M
TRVIadded+460,668$6.6M
IONSnew+132,339$5.91M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ORICexited-406,077-$4.4M
PCVXexited-66,793-$3.88M
ONCexited-12,273-$3.5M
VIRreduced-274,989-$3.07M
SIONexited-63,156-$2.78M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001931118-26-000011, largest first. % of portfolio is the value over $199,517,915, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 910,865 shares; 2025Q1: 774,721 shares; 2025Q2: 962,951 shares; 2025Q3: 361,408 shares; 2025Q4: 366,238 shares; 2026Q1: 225,158 shares; 2026Q2: 343,284 shares; 2026Q3: 597,408 shares 597,408$19.1M9.59%+254,124Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,268 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 37,433 shares; 2026Q1: 11,217 shares; 2026Q2: 53,916 shares; 2026Q3: 102,485 shares 102,485$18.9M9.47%+48,569Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 148,292 shares; 2026Q1: 251,566 shares; 2026Q2: 524,224 shares; 2026Q3: 984,892 shares 984,892$14.1M7.07%+460,668Timeline
GMABGENMAB A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 29,162 shares; 2026Q1: 196,709 shares; 2026Q2: 430,600 shares; 2026Q3: 365,662 shares 365,662$13M6.54%-64,938Timeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 98,160 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 199,209 shares; 2026Q2: 521,082 shares; 2026Q3: 918,231 shares 918,231$10.5M5.28%+397,149Timeline
ZLABZAI LAB LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 403,630 shares; 2025Q1: 294,947 shares; 2025Q2: 134,895 shares; 2025Q3: 200,628 shares; 2025Q4: 196,853 shares; 2026Q1: 275,818 shares; 2026Q2: 155,813 shares; 2026Q3: 362,671 shares 362,671$9.55M4.79%+206,858Timeline
ANLADLAI NORTYE GROUP LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 414,852 shares; 2026Q2: 552,501 shares; 2026Q3: 588,418 shares 588,418$9.41M4.72%+35,917Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 54,879 shares; 2026Q1: not reported; 2026Q2: 51,053 shares; 2026Q3: 41,784 shares 41,784$8.58M4.3%-9,269Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 88,308 shares; 2026Q1: 180,048 shares; 2026Q2: 287,583 shares; 2026Q3: 242,493 shares 242,493$7.86M3.94%-45,090Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 341,348 shares; 2025Q4: 288,677 shares; 2026Q1: 357,606 shares; 2026Q2: 208,368 shares; 2026Q3: 222,121 shares 222,121$7.5M3.76%+13,753Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 301,206 shares; 2025Q1: 423,632 shares; 2025Q2: 87,912 shares; 2025Q3: 87,912 shares; 2025Q4: 718,354 shares; 2026Q1: 387,371 shares; 2026Q2: 191,313 shares; 2026Q3: 184,392 shares 184,392$7.49M3.75%-6,921Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 4,874 shares; 2025Q3: not reported; 2025Q4: 9,451 shares; 2026Q1: 5,186 shares; 2026Q2: 7,172 shares; 2026Q3: 13,321 shares 13,321$7.22M3.62%+6,149Timeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 69,594 shares; 2025Q1: 160,442 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 357,359 shares 357,359$7.11M3.56%newTimeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 351,461 shares; 2026Q2: 188,282 shares; 2026Q3: 176,561 shares 176,561$6.72M3.37%-11,721Timeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 25,623 shares; 2026Q3: 178,842 shares 178,842$6.54M3.28%+153,219Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 150,312 shares; 2025Q4: not reported; 2026Q1: 730,548 shares; 2026Q2: 853,685 shares; 2026Q3: 578,696 shares 578,696$6.47M3.24%-274,989Timeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 98,267 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 132,339 shares 132,339$5.91M2.96%newTimeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 508,338 shares; 2025Q1: 966,203 shares; 2025Q2: 1,115,379 shares; 2025Q3: 1,309,236 shares; 2025Q4: 995,353 shares; 2026Q1: 1,585,977 shares; 2026Q2: 977,460 shares; 2026Q3: 1,017,817 shares 1,017,817$5.25M2.63%+40,357Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 423,006 shares 423,006$4.18M2.09%newTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 30,020 shares 30,020$2.97M1.49%newTimeline
DNAGINKGO BIOWORKS HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 222,553 shares 222,553$2.86M1.43%newTimeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 30,022 shares 30,022$2.67M1.34%newTimeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 53,950 shares; 2025Q4: 47,278 shares; 2026Q1: 13,311 shares; 2026Q2: 30,456 shares; 2026Q3: 48,045 shares 48,045$2.39M1.2%+17,589Timeline
KNSAKINIKSA PHARMACEUTICALS INTLQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 18,867 shares; 2026Q3: 31,684 shares 31,684$2.36M1.18%+12,817Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 755,599 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 980,768 shares; 2026Q1: 258,269 shares; 2026Q2: not reported; 2026Q3: 413,373 shares 413,373$2.01M1.01%newTimeline
LTGOLATIGO BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 88,178 shares 88,178$1.47M0.74%newTimeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 63,591 shares; 2026Q2: not reported; 2026Q3: 15,446 shares 15,446$1.29M0.64%newTimeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 192,139 shares; 2026Q2: 125,432 shares; 2026Q3: 118,304 shares 118,304$1.21M0.6%-7,128Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,129 shares; 2025Q1: 3,815 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,099 shares 2,099$1.06M0.53%newTimeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 822,293 shares; 2025Q1: 458,972 shares; 2025Q2: 1,060,764 shares; 2025Q3: 1,544,525 shares; 2025Q4: 2,253,550 shares; 2026Q1: 1,066,239 shares; 2026Q2: 1,278,652 shares; 2026Q3: 517,412 shares 517,412$993K0.5%-761,240Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 26,496 shares 26,496$985K0.49%newTimeline
TNXPTONIX PHARMACEUTICALS HLDG CQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 63,540 shares; 2026Q2: 63,648 shares; 2026Q3: 74,688 shares 74,688$727K0.36%+11,040Timeline
BOLDBOUNDLESS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 55,356 shares; 2026Q3: 206,242 shares 206,242$518K0.26%+150,886Timeline
GRALGRAIL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 3,238 shares 3,238$454K0.23%newTimeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 250,000 shares; 2025Q3: 250,000 shares; 2025Q4: 250,000 shares; 2026Q1: 250,000 shares; 2026Q2: 250,000 shares; 2026Q3: 225,872 shares 225,872$44.6K0.02%-24,128Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ORICORIC PHARMACEUTICALS INC406,077$4.4Mshares
PCVXVAXCYTE INC66,793$3.88Mshares
ONCBEONE MEDICINES LTD12,273$3.5Mshares
SIONSIONNA THERAPEUTICS INC63,156$2.78Mshares
ACRSACLARIS THERAPEUTICS INC257,675$1.36Mshares
HELPCYBIN INC204,424$1.35Mshares
TARAPROTARA THERAPEUTICS INC121,457$464Kshares
FTHFAETH THERAPEUTICS INC14,175$354Kshares
VYNEVYNE THERAPEUTICS INC61,269$39.9Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001931118-26-000011 base2026-11-16